drugset / Trial / NCT06740240
68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer
RandomizedParallel-groupOpen-labelDiagnostic
Summary
As a new dual targeting PET radiotracer, 68Ga-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-Biotin in patients with various types of cancer and compared them with the results of 68Ga-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 68Ga-FAPI.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2026-06-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | 18F-FDG | Diagnostic / imaging agent | 3.7 mbq/kg | Intravenous |
| Subject | 68Ga-FAPI-Biotin | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-FAPI-Biotin | Diagnostic / imaging agent | 148 mbq | Intravenous |
| Comparator | FAPI GA-68 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Comparator | FAPI GA-68 | Diagnostic / imaging agent | 148 mbq | Intravenous |